Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "IDA"

1676 News Found

Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr
News | November 14, 2022

Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr

The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022


Vinati Organics consolidated Q2FY23 PAT up 43% at Rs. 116 Cr
News | November 08, 2022

Vinati Organics consolidated Q2FY23 PAT up 43% at Rs. 116 Cr

The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.


GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr
News | November 04, 2022

GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr

The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022


Hester Biosciences Q2 FY23 consolidated profit up at Rs. 6.94 Cr
News | November 04, 2022

Hester Biosciences Q2 FY23 consolidated profit up at Rs. 6.94 Cr

The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022


GSK’s respiratory syncytial virus older adult vaccine candidate granted Priority Review by US FDA
Drug Approval | November 03, 2022

GSK’s respiratory syncytial virus older adult vaccine candidate granted Priority Review by US FDA

This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan


Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23
News | October 28, 2022

Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23

The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022


Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr
News | October 27, 2022

Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr

The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022


Novartis maintains growth momentum; Confirms FY’22 Group guidance
News | October 26, 2022

Novartis maintains growth momentum; Confirms FY’22 Group guidance

Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.


Jubilant Pharmova Q2FY23 consolidated PAT drops to Rs. 5.49 Cr
News | October 23, 2022

Jubilant Pharmova Q2FY23 consolidated PAT drops to Rs. 5.49 Cr

The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.